scholarly journals The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode

2014 ◽  
pp. 1589 ◽  
Author(s):  
Robert L. Findling ◽  
Lawrence Ginsberg
Keyword(s):  
Children And Adolescents ◽  
Extended Release ◽  
Open Label ◽  
Mixed Episode ◽  
Bipolar I Disorder

scholarly journals An Open-Label Study of Guanfacine Extended Release for Traumatic Stress Related Symptoms in Children and Adolescents

2013 ◽  
Vol 23 (4) ◽  
pp. 244-251 ◽  
Author(s):  
Daniel F. Connor ◽  
Damion J. Grasso ◽  
Michelle D. Slivinsky ◽  
Geraldine S. Pearson ◽  
Alok Banga
Keyword(s):  
Children And Adolescents ◽  
Traumatic Stress ◽  
Extended Release ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Long-Term Safety of Divalproex Sodium Extended-Release in Children and Adolescents with Bipolar I Disorder

2009 ◽  
Vol 19 (1) ◽  
pp. 83-89 ◽  
Author(s):  
Laura Redden ◽  
Melissa DelBello ◽  
Karen Dineen Wagner ◽  
Timothy E Wilens ◽  
Shishuka Malhotra ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Extended Release ◽  
Divalproex Sodium ◽  
Bipolar I Disorder

Long-Term, Open-Label Venlafaxine Extended-Release Treatment in Children and Adolescents with Major Depressive Disorder

CNS Spectrums ◽  
2007 ◽  
Vol 12 (3) ◽  
pp. 223-233 ◽  
Author(s):  
Graham J. Emslie ◽  
Paul P. Yeung ◽  
Nadia R. Kunz
Keyword(s):  
Major Depressive Disorder ◽  
Adverse Events ◽  
Depressive Disorder ◽  
Children And Adolescents ◽  
Extended Release ◽  
Pediatric Patients ◽  
Term Treatment ◽  
Open Label ◽  
Major Depressive

ABSTRACTIntroduction: Because major depressive disorder (MDD) is often chronic and recurrent, even pediatric patients who are treated successfully during an acute episode may need longer-term treatment. Yet, data on long-term treatment with antidepressants in pediatric MDD are limited.Objective: To evaluate long-term effectiveness and safety of treatment with venlafaxine extended-release (ER) in children and adolescents with MDD.Methods: Subjects (n=86) 7–17 years of age with MDD entered a multicenter, open-label study of flexible-dose venlafaxine ER for 6 weeks of acute treatment, followed by continuation treatment for up to 6 months total treatment. The primary efficacy variable was the Children's Depression Rating Scale-Revised (CDRS-R) total score (intent-to-treat population).Results: Mean CDRS-R total score decreased from 60.1±10.0 at baseline to 36.3±13.1 at week 6, and to 33.8±15.0 at 6 months (last observation carried forward). Among completers (n=36), the mean CDRS-R total score was 24.3±7.6 at the end of 6 months of treatment. The most frequent treatment-emergent adverse events were headache (53%), nausea (26%), infection (24%), abdominal pain (22%), vomiting (21%), and pharyngitis (19%). Fifteen (17%) participants discontinued due to adverse events, 9 of whom did so within the first 6 weeks. Serious adverse events (suicide attempt [two], hostility [two], hallucinations, depression, and pharyngitis) occurred in seven patients. There were no suicides.Conclusion: Most improvement with venlafaxine ER occurs during the first 6 weeks of treatment. Prescribers should be alert to signs of suicidal ideation and hostility in pediatric patients.

Sign in / Sign up

Export Citation Format

Share Document